We have published a new study. Click here to read de paper.

#28 Chronic Systemic Inflammation: A Silent Challenge for the World

Chronic systemic inflammation (CSI) is a complex biological process that has become a significant health issue worldwide, significantly impacting the European population. This article will delve into what CSI is, its economic and human costs to healthcare systems, its evolution over time, and its relationship with aging. Additionally, it will highlight the lack of effective biomarkers for early detection and how transcriptomics could aid in early detection as well as reversing it before it progresses into a chronic disease.

What Is Chronic Systemic Inflammation?

Chronic systemic inflammation (CSI) is a generalized inflammatory state in the body that can persist for an extended period without an apparent cause. Although it has been linked to several chronic diseases, early detection remains a significant challenge in medicine. This low-grade chronic inflammation can go unnoticed as it does not always present with obvious symptoms, but it may be associated with various chronic diseases such as cardiovascular diseases, type 2 diabetes, rheumatoid arthritis, Alzheimer’s disease, and certain types of cancer. To date, there are no definitive biomarkers for diagnosing CSI in its early stages.

The Economic Costs of CSI

CSI represents a substantial burden on healthcare systems worldwide in terms of economic costs. While quantifying direct and indirect costs precisely is challenging, several studies have shed light on this matter. Globally, CSI is estimated to cost over 3.7 trillion dollars annually in healthcare, as per a study published in the journal Nature Medicine in 2022. This study estimates that CSI accounts for approximately 10% of all healthcare costs worldwide, with higher costs associated with chronic diseases. Reducing CSI globally could have a significant impact on healthcare costs, with an estimated 25% reduction potentially saving up to 970 billion dollars annually in healthcare expenses.

According to the European Society of Cardiology’s 2019 report, cardiovascular diseases related to CSI represented an annual cost of over 210 billion euros in Europe. Additionally, direct medical expenses related to CSI, including doctor visits, medications, and hospitalizations, are also considerable. These costs can vary significantly depending on the country and the prevalence of CSI in the population.

CSI’s Per-Person Cost

Breaking down these costs per person is even more impactful. A study published in the journal Nature Medicine in 2022 estimated that the per-patient cost of healthcare due to CSI is approximately 10,000 dollars per year in the United States. Another study published in the Journal of the American Medical Association in 2021 estimated that the per-patient cost of healthcare due to CSI is approximately 5,000 dollars per year in Europe. The study found that costs were higher for individuals with severe CSI and those with associated chronic diseases.

The Human Costs and Associated Challenges

The human costs of CSI are equally significant. According to a recent study published in the medical journal “Frontiers in Immunology,” chronic systemic inflammation has been associated with a range of adverse health consequences affecting various body systems. This sustained inflammation has shown a negative impact on cardiovascular health, increasing the risk of diseases such as atherosclerosis and acute cardiovascular events. Moreover, CSI has been linked to insulin resistance and the progression of type 2 diabetes. Additionally, chronic systemic inflammation contributes to cognitive decline and the development of neurodegenerative disorders like Alzheimer’s disease. CSI can also have a significant psychological impact, contributing to the development of conditions such as depression and anxiety, further exacerbating the burden it places on individuals and society as a whole.

Evolution of CSI and Its Relationship with Aging

CSI tends to increase with age. As individuals age, their immune systems may become less efficient, leading to greater systemic inflammation. This poses additional challenges in a rapidly aging global society.

Unfortunately, the prevalence of unhealthy lifestyle habits has accelerated the aging process within the population, contributing to a downward trend in life expectancy worldwide. Factors such as poor diet, lack of exercise, and increased stress have played a significant role in this concerning trend, highlighting the urgent need for public health initiatives to promote healthier living and mitigate the negative impact on our aging societies.

The evolution of CSI is also linked to lifestyle factors such as diet, physical activity, and chronic stress, which can influence the onset and severity of CSI over time.

The Potential of Transcriptomics as a Biomarker

Transcriptomics is a branch of genomics that focuses on studying gene expression patterns, i.e., how genes are activated or deactivated in response to specific conditions. In the context of CSI, transcriptomics can offer valuable insights into genetic activity associated with chronic inflammation. By analyzing blood samples or other tissues, scientists can identify gene expression patterns characteristic of CSI. These patterns may include the overexpression of genes related to inflammation or the suppression of genes associated with immune regulation. Identifying these patterns using transcriptomic techniques could serve as an effective biomarker for early detection of CSI.


Chronic systemic inflammation represents a challenge in early detection and effective diagnosis due to the lack of definitive biomarkers. However, transcriptomics and the analysis of metabolic pathways offer hope in this regard. These techniques provide a deeper understanding of genetic and metabolic activity associated with CSI, which could lead to the development of precise and effective biomarkers. Advancements in molecular research and the application of high-precision techniques are essential for identifying biomarkers that enable early detection of CSI, which, in turn, could help reduce the economic and human costs associated with this condition. The future of precision medicine and early detection of CSI largely depends on these scientific advances.

Follow us: